Your browser doesn't support javascript.
loading
Evidence requirements of permanently listed digital health applications (DiGA) and their implementation in the German DiGA directory: an analysis.
Mäder, Melanie; Timpel, Patrick; Schönfelder, Tonio; Militzer-Horstmann, Carsta; Scheibe, Sandy; Heinrich, Ria; Häckl, Dennis.
Afiliação
  • Mäder M; Faculty of Economics and Management Science, Leipzig University, Chair for Health Economics and Management, Leipzig, Germany. melanie.maeder@wig2.de.
  • Timpel P; Scientific Institute for Health Economics and Health System Research (WIG2 GmbH), Markt 8, 04109, Leipzig, Germany. melanie.maeder@wig2.de.
  • Schönfelder T; Scientific Institute for Health Economics and Health System Research (WIG2 GmbH), Markt 8, 04109, Leipzig, Germany.
  • Militzer-Horstmann C; Scientific Institute for Health Economics and Health System Research (WIG2 GmbH), Markt 8, 04109, Leipzig, Germany.
  • Scheibe S; Department of Health Sciences/Public Health, Dresden University, Dresden, Germany.
  • Heinrich R; Faculty of Economics and Management Science, Leipzig University, Chair for Health Economics and Management, Leipzig, Germany.
  • Häckl D; Scientific Institute for Health Economics and Health System Research (WIG2 GmbH), Markt 8, 04109, Leipzig, Germany.
BMC Health Serv Res ; 23(1): 369, 2023 Apr 17.
Article em En | MEDLINE | ID: mdl-37069592
ABSTRACT

BACKGROUND:

With its digital health application (DiGA)-system, Germany is considered one of Europe's pioneers in the field of evidence-based digital health. Incorporating DiGA into standard medical care must be based on evidence-based success factors; however, a comprehensive overview of the evidence required of scientific studies for their approval is lacking.

OBJECTIVE:

The study aims to, (1) identify specific requirements defined by the Federal Institute for Drugs and Medical Devices (German Bundesinstitut für Arzneimittel- und Medizinprodukte; BfArM) to design adequate studies, proving a positive healthcare effect, and (2) to assess the evidence given for applications permanently listed in the DiGA directory.

METHODS:

A multi-step approach was used (1) identification of the evidence requirements for applications permanently listed in the DiGA directory, (2) identification of the evidence available supporting them.

RESULTS:

All DiGA permanently listed in the DiGA directory (13 applications) are included in the formal analysis. Most DiGA addressed mental health (n = 7), and can be prescribed for one or two indications (n = 10). All permanently listed DiGA have demonstrated their positive healthcare effect through a medical benefit, and most of them provide evidence for one defined primary endpoint. All DiGA manufacturers conducted a randomized controlled trial.

DISCUSSION:

It is striking that- although patient-relevant structural and procedural improvements show high potential for improving care, especially in terms of processes - all DiGA have provided a positive care effect via a medical benefit. Although BfArM accepts study designs with a lower level of evidence for the proof of a positive healthcare effect, all manufacturers conducted a study with a high level of evidence.

CONCLUSION:

The results of this analysis indicate that permanently listed DiGA meet higher standards than required by the guideline.
Assuntos
Palavras-chave

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa Tipo de estudo: Clinical_trials / Prognostic_studies / Qualitative_research Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa Tipo de estudo: Clinical_trials / Prognostic_studies / Qualitative_research Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article